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1. Introduction 
The pathogenesis of the disease myasthenia gravis 
(MG) and its animal model experimental autoimmune 
myasthenia gravis (EAMG) involves an autoimmune 
reaction to nicotinic acetylcholine receptor (nAcChR) 
[l--5], where anti-nAcChR antibodies effectively 
impair transmission at the neuromuscular junction 
[ 1,6]. Hence, the immunogenic properties of nAcChR 
are of major consideration. The ability to differen- 
tiate the antigenic determinants of nAcChR would be 
of great use by permitting a itetailed analysis of the 
importance of different determinants in MG, as well 
as providing a new dimension for structural and func- 
tional studies of nAcChR. 
The lymphocyte hybridization procedure provides 
an opportunity to develop such antigenic site-specific 
monoclonal antibodies (mAb) [7]. We have applied 
the procedure to nAcChR and report the isolation, 
in particular, of mAbs directed: (i) at the neuro- 
transmitter-binding site; (ii) close to the neurotrans- 
mitter-binding site. These mAbs should help delineate 
the contribution of this region of nAcChR to the 
pathogenesis of MG. 
2. Materials and methods 
2.1. Immunization, fusion and cell culture 
nAcChR was purified from the electric organ of 
Torpedo mannorata [8]. 3 BALB/c mice (3 months 
old) were injected intraperitoneally with nAcChR 
(0.5 mg), at day 0 in complete Freund’s adjuvant and 
at day 12 in 150 mM NaCl, 10 mM Na-phosphate 
(PBS) (pH 7.2). 
One mouse was sacrificed 3 days later and the 
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spleen removed. Spleen cells (1 08) were fused with 
the non-secreting B-lymphocytoma cell line SP2- 
OAg14 (10’ cells) by treating with 50% (v/v) poly- 
ethylene glycol 1500 (37OC!, 1.5 min) [9]. The cell 
mixture was distributed in 96 Costar tray wells 
(2 X 10’ cells/well) with a feeder layer of macro- 
phages (4 X 1 OS cells/well). On the second day in 
culture, HAT (hypoxanthine/aminopterin/thymidine) 
medium was added. Supernatants were assayed for 
anti-nAcChR activity after 21 days in culture, and 
cells were cloned by limited dilution [lo]. Harvested 
cells were frozen in HAT medium containing 10% 
(v/v) dimethylsulphoxide, and stored in liquid 
nitrogen. 
2.2. Radioimmunoassays 
The antigen used was ‘251-labelled nAcChR (r2’I- 
nAcChR) [ 111. The specific activity of different 
preparations varied from 2.4-3.0 X lo5 cpm/pmol 
toxin binding site, as calibrated by the filtration assay 
[ 121. Initially, the radioimmunoassay (RIA) was per- 
formed by a double antibody procedure, incubating 
(37’C, 60 min) conditioned medium with 1251- 
nAcChR (0.3 pmol) and precipitating the immune 
complex with rabbit anti-mouse immunoglobulin G 
(RAMIG) serum (37’C, 60 min then 4’C!, 16 h). 
Later, a solid-phase RIA was used, based on an anti- 
body adsorbent of bacterial protein A (PA) that was 
prepared and stored as a 10% (v/v) suspension [ 131. 
RIA was performed in PBS containing 0.05% (v/v) 
Emulphogen BC720 (PBSEOS) (total vol. 0.25 ml) 
by incubating (room temp., 30 min) conditioned 
medium with ‘2SI-nAcChR (0.3 pmol). Immune com- 
plexes were precipitated by adding excess PA (5 min 
incubation) and centrifuging (2500 X g, 10 min, 
4’C). The pellet was washed with 2 X 4 ml PBSEOS, 
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then counted. In some clones, it was necessary to 
include RAMIG (incubation at room temperature, 
30 min) to act as a link between mouse IgG subclass 
I-nAcChR complexes and PA [14]. 
Table 1 
Effect of RAMIG on the protein A assay 
Clone ~ax~al-fold increase in titre 
in presence of RAbfIG 
2.3. Effects of ligands on binding of mA bs to 
nAcChR 
Effects of various choline&z ligands on binding 
of antibodies to ‘251-nAcChR were tested as follows, 
The ligand was preincubated for 30-60 min at room 
temperature with receptor (0.3 pmol), then with 
conditioned medium (30 min). The immune complex 
was harvested as above, using the PA procedure. 
1 64.0 
2 65.1 
3 2.5 
4 2.0 
5 No effect 
RI-4 was performed as in section 2. Aliquots of conditioned 
medium were incubated first with ‘*‘I-nAcChR (0.3 pmol) 
then with increasing amounts (0.1-l 2.5 fig) of purified 
RAMIG. Sufficient PA was added to precipitate all IgG. 
Results are the averages of 2 expt. and are expressed as: 
Titer (presence of RAMIG)]/]Titer (absence of RAMIG)] 
3. Results 
3.1. Cell fusion and cloning 3.2. Effect of RAMG’ on assay of rnAb 
All 96 Costar wells contained growing hybridomas, 
of which 61 (63.5%) were secreting anti-nAcChR 
antibodies. The cells from 37 of the original wells 
were frozen. 
The extent to which conditioned medium inhib- 
ited binding of ‘2SI-labelled mono-iodo cr-bungaro- 
toxin (ar-Bgt) to nAcChR-rich membrane fragments 
was used as a pre~rn~a~ screening process for select- 
ing cells for cloning (not shown) as we wished to 
identify mAbs binding to nAcChR exposed at the cell 
membrane. The cells from 3 wells showing a high 
degree of inhibition of toxin binding were cloned. 
Five, stable, monoclonal lines were established. These 
are labelled 1-5 
Table 1 illustrates the effects of adding RAMIG 
in RIA using PA. The large increases in titers for 
clones 1 and 2 indicate that they belong to mouse 
IgG subclass I [ 141. RAMIG had a less marked effect 
on the titers of clones 3 and 4, and had no effect on 
clone 5. 
3.3. Effect of c~ol~n~~~ ligands on mA b binding to 
nA&lR 
The results are depicted in table 2. mAbs of 
clones 1 and 2 were inhibited by all ligands tested, 
whilst those of clones 4 and 5 were inhibited only by 
o-Bgt. mAbs of clone 3 were unaffected by the two 
nicotinic antagonists ested, and atropine, but showed 
Table 2 
Effects of ligands on RIA using protein A 
Clone Control 
binding 
@pm) 
Binding in the presence of ligand (% of control binding) 
~b~yl~o~e d-~~c~~~e Atropine Ix-Bgt 
1 10 271 * 387 56.9 i 3.7 4.3 f 1.1 78.7 i 2.3 0 
2 22 827 f 600 69.9 ?r 1.5 2.8 f 1.9 85.7 * 1.1 0 
3 10 833 f 643 85.3 * 2.0a 98.3 * 3.6 101.4 f 1.6 103.7 * 2.8 
4 4513* 32 100.1 f 3.2 105.4 f 7.5 104.9 * 7.6 17.7 f 1.8 
5 1297 f 87 95.4 * 3.5 115.5 f 4.1a 115.1 f 8.3 0 
a Significant at p = 0.05 using Student’s t-test 
The antibody activities of the monodonal lines were assayed ushtg PA, after preincubation of ra*I- 
nAcChR (0.3 pmol) with cholinergic ligands. With clones 1-4, RAMIG (10 fig, 5 ~1) was included 
in the incubation mixture. Control binding was established in the absence of ligands. Ligand was 
1 X lo-’ M (~bamyl~oBne, d-tubocurarine and atropine) and 1 X lo-’ M (a-&$). Results are 
expressed as % of control binding *SD (n = 4). The analyses were performed on at least 2 separate 
occasions 
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Fig 1. Dose-response curves for the effects of carbamyl- 
choline (A) and d-tubocurarine (B) on binding of mAbs of 
clone 1 to *WI-nAcChR (section 2). RAMIG (10 erg, 5 gl) was 
included in the incubation mixture. Results *SD (n = 4) are 
expressed as % of binding in the absence of ligairds ((A) 
7655 t 142 cpm; (B) 14460 f: 216 cpm). Analyses were per- 
formed on at least 2 separate occasions. 
a significant, 15% decrease in the presence of the ago- 
nist carbamylcholine. Clone 1 was studied in greater 
detail. Dose-response curves Indicated that half- 
maximal inhibition (1&l of antibody binding to 
nAcChR was achieved at 1 X lo4 M carbamylcholine 
and 1 X 1 O-’ M d-tubocurarine (fig. 1). A similar 
analysis using cr-Bgt gave an 1se of 2.3 X IO+ M 
(fig.2A). An identical value was obtained with cw-Bgt 
using clone 5 (fig.2B). 
4. Discussion 
One approach to studying MG is the induction of 
EAMG by passive transfer of anti-nAcChR antibodies 
[2,3]. Combined with mAbs, it may allow the iden- 
tification of determinants of particular importance 
Fig.2. Dose-response curves of the effects of a-Bgt on bind- 
ing of antibodies of clones 1 (A) and 5 (B) to *aaI-nAcChR 
(section 2). For clone 1, RAMIG (10 M, 5 pi) was induded 
in the incubation mixture. Results *SD (rz = 4) are expressed 
as 970 of binding in the absence of cu-Bgt ((A) 8062 f 621 cpm; 
(B) 5551 f 240 cpm). Analyses were performed on at least 
2 separate occasions. 
in the disease. Obviously, it necessitates that the 
mAbs bind to nAcChR in situ and a preliminary 
requirement isto identify such antibodies. Four of 
the five clones established meet his requirement. 
Clones 1 and 2 are probably secreting the same 
mAb as results with RAMIG (table 1) and cholinergic 
ligands (table 2) are similar. Moreover, dose-response 
curves, most notably those with the small mol. wt 
ligands (fig.2A,B) indicate that the antibody is bind- 
ing at the neurotransmitter binding site of the recep- 
tor. The 1se values reflect the affinities of the ligands 
for nA&!hR [I 5,161. Atropine also i~~b~ts binding 
of the mAb to nAcChR, although to a much lesser 
extent and only at a high concentration (1 O4 M). 
The binding of mAbs of clones 4 and 5 is inhibited 
by cuBgt; none of the smaller ligands had an effect 
(table 2, Iig3B). These mAbs bind close to, but not 
at, the neurotransmitter-binding siteof nAcChR. 
Moreover, the studies with RAMIG (table 1) suggest 
that these antibodies are not identical and they may 
therefore be directed against different determinants. 
The mAb secreted by clone 3 was partially 
affected only by the presence of the nicotinic agonist 
carbamylcho~e. One possible xplanation isthat the 
antibody binds to a determinant affected by confor- 
mational changes induced in nAcChR by binding of 
the agonist. A stereochemic inhibition of binding of 
the mAb to nAcChR is ruled out because toxin had 
no effect. 
Four reports have appeared escribing mAbs 
against nAcChR f17-201. Gomez et al. f17] describe 
one mAb whose binding to nAcChR is completely 
inhibited by a-Bgt, but no other ligand. Thus, it is 
similar to mAbs 4 and 5 above. Tzartos and Lindstrom 
(one monoclonal line, [ 181) and Lennon and Lambert 
(2 rnonoclonal lines, [19]) both report the passive 
transfer of EAMG with mAbs whose determinants are 
remote from the neurotransmitter binding site of 
nAcChR. 
Thus the importance of different antigenic deter- 
minants of nAcChR for inducing EAMG is slowly 
being unravelled. The mAbs described in this report 
will be pa~icularly useful for analysing the contribu- 
tion of determinants in the region of the neurotrans- 
mitter binding site. 
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